Table 1 Model inputs
Variable | Base case | Low value | High value | Source | |
|---|---|---|---|---|---|
Pre-surgery | |||||
Mydrane®: Percentage of mydriasis failure during surgery needing additional mydriatic treatments | |||||
Mydrane® | 1.1% | 0.2% | 3.2% | Phase III clinical trial results, Confidence Interval 95% [9] | |
Eye drops | 5.3% | 3.0% | 8.7% | ||
Number of eye drop instillation sessions by nurses | 3 | 2 | 4 | Assumption | |
Duration of one session of eye drop (min) | 3 | 1.5 | 5 | Assumption, Mydriasert report, Office for National Statistics [15] | |
Number of patients per vial of eye drops | 1 | 1 | 5 | Assumption, Mydriasert report, Office for National Statistics [15] | |
Patient waiting time before surgery (min) | |||||
Mydrane® | 8.70 | 8.19 | 9.21 | Phase III clinical trial results, Confidence Interval 95% [9] | |
Eye drops | 37.90 | 36.73 | 39.07 | ||
Nurse cost/h in £ | 43.12 | 35.76 | 59.95 | PSSRU 2012–2013, Lower: nurse day ward without qualification costs, Higher: nurse team manager [16] | |
During surgery | |||||
Mydrane®: Surgeon working time (no mydriasis failure) (min) | 12.03 | 11.51 | 12.52 | Phase III clinical trial results [9], Phase II clinical trial results, Confidence Interval 95% | |
Eye drops: Surgeon working time (no mydriasis failure) (min) | 11.34 | 10.64 | 12.04 | Phase III clinical trial results, Confidence Interval 95% [9] | |
Mydrane®: Operation room occupancy time (min) | 12.03 | 11.51 | 12.52 | Phase III clinical trial results [9], Phase II clinical trial results, Confidence Interval 95% | |
Eye drops: Operation room occupancy time (min) | 11.34 | 10.64 | 12.04 | Phase III clinical trial results [9], Confidence Interval 95% | |
Mydrane®: Additional time needed if mydriasis failure (min) | 10.00 | 2.50 | 7.50 | UK, 2013, Molecule used for additional mydriasis, European Observatory for Cataract Surgery 2014 [7] | |
Eye drops: Additional time needed if mydriasis failure (min) | 10.00 | 2.50 | 7.50 | UK, 2013, Molecule used for additional mydriasis, European Observatory for Cataract Surgery 2014 [7] | |
Mydrane®: Surgeon time loss between operations caused by mydriasis failure (min) | 10.00 | 5.00 | 20.00 | Assumption | |
Eye drops: Surgeon time loss between operations caused by mydriasis failure (min) | 10.00 | 5.00 | 20.00 | Assumption | |
Additional mydriatic treatments distribution (more than 1 possible) | Adrenaline | 4% | 39% | 4% | UK, 2013, Molecule used for additional mydriasis, European Observatory for Cataract Surgery 2014 [7] |
Phenylephrine | 93% | 57% | 93% | ||
Tropicamide | 14% | 0% | 14% | ||
Mechanical tools | 4% | 5% | 4% | ||
Cyclopentolate | 32% | 1% | 32% | ||
Others | 0% | 0% | 0% | ||
Cost Mydrane® in £ | 6.00 | 3.00 | 9.00 | Assumption | |
Cost Adrenaline in £ | 4.95 | 0.39 | 8.31 | British National Formulary 2015 [17] | |
Cost Phenylephrine in £ | 0.57 | 0.57 | 0.57 | British National Formulary 2015 [17] | |
Cost Tropicamide in £ | 0.54 | 0.50 | 1.60 | British National Formulary 2015 [17] | |
Cost Mechanical tools in £ | 56.80 | 28.40 | 85.20 | Mydriasert pupillary dilation for cataract surgery. | |
Costs Cyclopentolate in £ | 0.56 | 0.50 | 12.96 | British National Formulary 2014 | |
Surgeon cost/h in £ | 147.26 | 105.18 | 189.33 | Lower: consultant surgery without costs including qualifications, Upper: assumption | |